142 related articles for article (PubMed ID: 19460283)
1. Obstacles to the implementation of antiemetic guidelines.
Grunberg SM
J Natl Compr Canc Netw; 2009 May; 7(5):601-5. PubMed ID: 19460283
[TBL] [Abstract][Full Text] [Related]
2. Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines.
Mertens WC; Higby DJ; Brown D; Parisi R; Fitzgerald J; Benjamin EM; Lindenauer PK
J Clin Oncol; 2003 Apr; 21(7):1373-8. PubMed ID: 12663729
[TBL] [Abstract][Full Text] [Related]
3. [Region-wide professional practice evaluation with regards to antiemetic prescription into chemotherapy-induced nausea and vomiting].
Tavernier J; Jouannet-Romaszko M; Bertucat H; Marchiset N; Bahadoor M; Chevrier R
Bull Cancer; 2016; 103(7-8):622-31. PubMed ID: 27178880
[TBL] [Abstract][Full Text] [Related]
4. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations.
Jordan K; Sippel C; Schmoll HJ
Oncologist; 2007 Sep; 12(9):1143-50. PubMed ID: 17914084
[TBL] [Abstract][Full Text] [Related]
5. Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life.
Abunahlah N; Sancar M; Dane F; Özyavuz MK
Int J Clin Pharm; 2016 Dec; 38(6):1464-1476. PubMed ID: 27796777
[TBL] [Abstract][Full Text] [Related]
6. Cohort study of consistency between the compliance with guidelines for chemotherapy-induced nausea and vomiting and patient outcome.
Inoue M; Shoji M; Shindo N; Otsuka K; Miura M; Shibata H
BMC Pharmacol Toxicol; 2015 Mar; 16():5. PubMed ID: 25889295
[TBL] [Abstract][Full Text] [Related]
7. 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I; Ruhlmann CH; Jahn F; Schwartzberg L; Rapoport B; Rittenberg CN; Clark-Snow R
Support Care Cancer; 2017 Jan; 25(1):297-301. PubMed ID: 27572335
[TBL] [Abstract][Full Text] [Related]
8. A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting.
Hesketh PJ; Aapro M; Jordan K; Schwartzberg L; Bosnjak S; Rugo H
Biomed Res Int; 2015; 2015():651879. PubMed ID: 26421300
[TBL] [Abstract][Full Text] [Related]
9. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the compliance with antiemetic guidelines for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancy.
Uchida M; Nakamura T; Shima T; Mori Y; Yoshimoto G; Kato K; Shimokawa M; Hosohata K; Miyamoto T; Akashi K
Pharmazie; 2019 Apr; 74(4):250-254. PubMed ID: 30940311
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses.
Clark-Snow R; Affronti ML; Rittenberg CN
Support Care Cancer; 2018 Feb; 26(2):557-564. PubMed ID: 28871358
[TBL] [Abstract][Full Text] [Related]
12. Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center.
Nolte MJ; Berkery R; Pizzo B; Baltzer L; Grossano D; Lucarelli CD; Kris MG
J Clin Oncol; 1998 Feb; 16(2):771-8. PubMed ID: 9469369
[TBL] [Abstract][Full Text] [Related]
13. Antiemetic Guidelines: Using Education to Improve Adherence and Reduce Incidence of CINV in Patients Receiving Highly Emetogenic Chemotherapy.
Mellin C; Lexa M; Leak Bryant A; Mason S; Mayer DK
Clin J Oncol Nurs; 2018 Jun; 22(3):297-303. PubMed ID: 29781466
[TBL] [Abstract][Full Text] [Related]
14. Adherence to and Implementation of ASCO Antiemetic Guidelines in Routine Practice in a Tertiary Cancer Center in India.
Patil VM; Noronha V; Joshi A; Ramaswamy A; Gupta S; Sahu A; Doshi V; Gupta T; Rath S; Banavali S; Prabhash K
J Oncol Pract; 2017 Jun; 13(6):e574-e581. PubMed ID: 28486012
[TBL] [Abstract][Full Text] [Related]
15. [Prevention and control of chemotherapy-induced nausea and vomiting].
Gómez-Raposo C; Feliú-Batlle J; González-Baróna M
Med Clin (Barc); 2006 Feb; 126(4):143-51. PubMed ID: 16472500
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment.
Jordan K; Kasper C; Schmoll HJ
Eur J Cancer; 2005 Jan; 41(2):199-205. PubMed ID: 15661543
[TBL] [Abstract][Full Text] [Related]
17. Antiemetic overuse in patients receiving chemotherapy.
Das M
Lancet Oncol; 2016 Oct; 17(10):e428. PubMed ID: 27667572
[No Abstract] [Full Text] [Related]
18. Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting.
Berard CM; Mahoney CD
Am J Health Syst Pharm; 1995 Sep; 52(17):1879-85. PubMed ID: 8528849
[TBL] [Abstract][Full Text] [Related]
19. State of the Art Antiemetic Therapy for Cancer Patients.
Lau TK; Yip CH; Yeo W
Curr Oncol Rep; 2016 Jan; 18(1):2. PubMed ID: 26694923
[TBL] [Abstract][Full Text] [Related]
20. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
